Maya Sterling1, Zubaida Al-Ismaili1, Kelly R McMahon1, Melissa Piccioni1, Michael Pizzi1, Theresa Mottes2, Larry C Lands3, Sharon Abish4, Adam J Fleming5, Michael R Bennett2, Ana Palijan1, Prasad Devarajan2, Stuart L Goldstein2, Maureen M O'Brien6, Michael Zappitelli1. 1. Division of Nephrology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada. 2. Department of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Division of Respirology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada. 4. Division of Hematology-Oncology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada. 5. Division of Hematology-Oncology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 6. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
BACKGROUND: Cisplatin (Cis), carboplatin (Carb), and ifosfamide (Ifos) are common nephrotoxic chemotherapies. Biomarkers of tubular injury may allow for early acute kidney injury (AKI) diagnosis. PROCEDURE: We performed a two-center (Canada, United States) pilot study to prospectively measure serum creatinine (SCr), urine neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 (IL-18) in children receiving Cis/Carb (27 episodes), Ifos (30 episodes), and in 15 hospitalized, nonchemotherapy patients. We defined AKI using the Kidney Disease Improving Global Outcomes (KDIGO) definition. We compared postchemotherapy infusion NGAL and IL-18 concentrations (immediate postdose to 3 days later) to pre-infusion concentrations. We calculated area under the receiver operating characteristic curve (AUC) for postinfusion biomarkers to discriminate for AKI. RESULTS: Prechemotherapy infusion NGAL and IL-18 concentrations were not higher than nonchemotherapy control concentrations. Increasing chemotherapy dose was associated with increasing postinfusion (0-4 hr after infusion) NGAL (P < 0.05). Post-Ifos, immediate postdose, and daily postdose NGAL and IL-18 were significantly higher than pre-infusion biomarker concentrations (P < 0.05), during AKI episodes. NGAL and IL-18 did not rise significantly after Cis-Carb infusion, relative to predose concentrations (P > 0.05). NGAL and IL-18 measured immediately after Ifos infusion discriminated for AKI with AUCs is 0.80 (standard error = 0.13) and 0.73 (standard error = 0.16), respectively. NGAL and IL-18 were not diagnostic of Cis-Carb-associated AKI. When AUCs were adjusted for age, all biomarker AUCs (Cis-Carb and Ifos) improved. CONCLUSION: Urine NGAL and IL-18 show promise as early AKI diagnostic tests in children treated with ifosfamide and may have a potential role in drug toxicity monitoring.
BACKGROUND:Cisplatin (Cis), carboplatin (Carb), and ifosfamide (Ifos) are common nephrotoxic chemotherapies. Biomarkers of tubular injury may allow for early acute kidney injury (AKI) diagnosis. PROCEDURE: We performed a two-center (Canada, United States) pilot study to prospectively measure serum creatinine (SCr), urine neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 (IL-18) in children receiving Cis/Carb (27 episodes), Ifos (30 episodes), and in 15 hospitalized, nonchemotherapy patients. We defined AKI using the Kidney Disease Improving Global Outcomes (KDIGO) definition. We compared postchemotherapy infusion NGAL and IL-18 concentrations (immediate postdose to 3 days later) to pre-infusion concentrations. We calculated area under the receiver operating characteristic curve (AUC) for postinfusion biomarkers to discriminate for AKI. RESULTS: Prechemotherapy infusion NGAL and IL-18 concentrations were not higher than nonchemotherapy control concentrations. Increasing chemotherapy dose was associated with increasing postinfusion (0-4 hr after infusion) NGAL (P < 0.05). Post-Ifos, immediate postdose, and daily postdose NGAL and IL-18 were significantly higher than pre-infusion biomarker concentrations (P < 0.05), during AKI episodes. NGAL and IL-18 did not rise significantly after Cis-Carb infusion, relative to predose concentrations (P > 0.05). NGAL and IL-18 measured immediately after Ifos infusion discriminated for AKI with AUCs is 0.80 (standard error = 0.13) and 0.73 (standard error = 0.16), respectively. NGAL and IL-18 were not diagnostic of Cis-Carb-associated AKI. When AUCs were adjusted for age, all biomarker AUCs (Cis-Carb and Ifos) improved. CONCLUSION: Urine NGAL and IL-18 show promise as early AKI diagnostic tests in children treated with ifosfamide and may have a potential role in drug toxicity monitoring.
Authors: Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson Journal: Eur J Cancer Date: 2009-10-21 Impact factor: 9.162
Authors: A Jin Won; Siwon Kim; Yoon Gyoon Kim; Kyu-Bong Kim; Wahn Soo Choi; Sam Kacew; Kyeong Seok Kim; Jee H Jung; Byung Mu Lee; Suhkmann Kim; Hyung Sik Kim Journal: Mol Biosyst Date: 2016-01
Authors: Michael Zappitelli; Kimberly K Washburn; Ayse A Arikan; Laura Loftis; Qing Ma; Prasad Devarajan; Chirag R Parikh; Stuart L Goldstein Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Kelly R McMahon; Maya Harel-Sterling; Michael Pizzi; Louis Huynh; Erin Hessey; Michael Zappitelli Journal: Pediatr Nephrol Date: 2018-09-14 Impact factor: 3.714
Authors: Kelly R McMahon; Hayton Chui; Shahrad Rod Rassekh; Kirk R Schultz; Tom D Blydt-Hansen; Cherry Mammen; Maury Pinsk; Geoffrey D E Cuvelier; Bruce C Carleton; Ross T Tsuyuki; Colin J D Ross; Prasad Devarajan; Louis Huynh; Mariya Yordanova; Frédérik Crépeau-Hubert; Stella Wang; Vedran Cockovski; Ana Palijan; Michael Zappitelli Journal: Kidney360 Date: 2021-11-03
Authors: Leonardo Trasande; Sandra India Aldana; Howard Trachtman; Kurunthachalam Kannan; Deborah Morrison; Dimitri A Christakis; Kathryn Whitlock; Mary Jo Messito; Rachel S Gross; Rajendiran Karthikraj; Sheela Sathyanarayana Journal: Environ Pollut Date: 2019-10-23 Impact factor: 8.071
Authors: Eryk Latoch; Katarzyna Konończuk; Katarzyna Taranta-Janusz; Katarzyna Muszyńska-Rosłan; Edyta Szymczak; Anna Wasilewska; Maryna Krawczuk-Rybak Journal: Cancer Chemother Pharmacol Date: 2020-10-14 Impact factor: 3.333